Joyce O’Shaughnessy, MD: Treatment Goals for Patients With TNBC and Multiple Metastatic Sites

The IMpassion130 Study in Metastatic TNBCПодробнее

Joyce O’Shaughnessy, MD: Treatment Goals for Patients With TNBCПодробнее

Joyce O’Shaughnessy, MD: Fourth-Line Considerations in Metastatic TNBCПодробнее

Dr. O'Shaughnessy on Precision Medicine in Triple Negative Breast CancerПодробнее

Joyce O'Shaughnessy, MD explains the importance of The School of Breast OncologyПодробнее

Dr. Joyce O’Shaughnessy on Promising Agents in Triple-Negative Breast CancerПодробнее

Joyce O’Shaughnessy, MD: Principle Third-Line Options for Patients With Metastatic TNBCПодробнее

Joyce O’Shaughnessy, MD: Third-Line Options to Prolong LifeПодробнее

Joyce O’Shaughnessy, MD: Candidacy for Eribulin TherapyПодробнее

Dr. O'Shaughnessy on the Utility of Capivasertib in Targeting Akt in Breast CancerПодробнее

Dr. O'Shaughnessy on Role of Chemotherapy in Future TNBC TreatmentПодробнее

Joyce O’Shaughnessy, MD, on the role of CDK4/6 inhibitors in the management of TNBCПодробнее

Dr. Joyce O'Shaughnessy on Eribulin in Metastatic Breast CancerПодробнее

Joyce O’Shaughnessy, MD: Fourth-Line ConsiderationsПодробнее

Dr. Joyce O'Shaughnessy on Treatment With Everolimus in Advanced Breast CancerПодробнее

Joyce O’Shaughnessy, MD: Candidacy for Eribulin TherapyПодробнее

Joyce O'Shaughnessy, MD discusses the importance of IBC 2018Подробнее

Joyce O’Shaughnessy, MD: Third-Line Options Available to Prolong Life in TNBCПодробнее

Dr. Joyce O'Shaughnessy Invites you to SOBO 2020 in Atlanta, GA November 5-7thПодробнее